Observational study of the minimally invasive method for detecting amyloid-beta and tau protein

Observational study of the minimally invasive method for detecting amyloid-beta and tau protein - Observational study of the minimally invasive method for detecting amyloid-beta and tau protein

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008982

Enrollment

Registered

2012-09-26

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: People who are over 20 years old and satisfy the following (1) or (2) (1) Probable Alzheimer's disease patients a) Patients who are diagnosed probable Alzheimer's disease according to NIAA guideline b) Informed consent by the patient or guardian (2) Normal individuals or patients without any of neurological diseases (G00-G99) classified by ICD10 a) Informed consent b) Patients who are not prescribed medicines for neurological disease

Exclusion criteria

Exclusion criteria: 1) People having nose disease such as sinusitis 2) People with bleeding tendency 3) Patients who were judged inappropriate for the study by the investigator

Design outcomes

Primary

Measure	Time frame
Comparison of the levels of amyloid-beta and tau protein in the nasal cavity between young and senior normal individuals and Alzheimer's disease patients	—

Secondary

Measure	Time frame
1) Relationship between the aging and the levels of amyloid-beta and tau protein in the nasal cavity 2) Relationship between the score of MMSE and the levels of amyloid-beta and tau protein in the nasal cavity 3) Relationship between the blood test and the levels of amyloid-beta and tau proteins in the nasal cavity 4) Relationship the levels of amyloid-beta and tau protein between the blood and the nasal cavity 5) Relationship between the levels of amyloid-beta and tau proteins in the nasal cavity	—

Measure

Time frame

1) Relationship between the aging and the levels of amyloid-beta and tau protein in the nasal cavity 2) Relationship between the score of MMSE and the levels of amyloid-beta and tau protein in the nasal cavity 3) Relationship between the blood test and the levels of amyloid-beta and tau proteins in the nasal cavity 4) Relationship the levels of amyloid-beta and tau protein between the blood and the nasal cavity 5) Relationship between the levels of amyloid-beta and tau proteins in the nasal cavity

—

Countries

Japan

Outcome results